Frank Facchini '90 is Chief Medical Officer for Interventional Oncology at Varian
September 17, 2019
Francis R. Facchini, a 1990 graduate of DePauw University, has been appointed chief medical officer, intervential oncology, for Varian (NYSE: VAR). In his new post, "Dr. Facchini has global responsibility for overseeing all aspects of this area including ongoing development of Varian's innovative IO treatment offerings, clinical strategy, and helping advance the field of interventional oncology as an important pillar of patient care," notes an announcement.
Facchini was most recently chief medical officer and head of medical affairs for BTG Plc. "where he had responsibility for developing and commercializing products targeting critical care, cancer, vascular and other disorders." He previously served as global director of medical and clinical affairs for Angiodynamics, Inc. and was chief medical officer of Navilyst Medical, Inc.
"Frank will be a great addition to the Varian Medical Affairs team," said Dee Khuntia, Varian chief medical officer. "He is a strategic thinker with strong business acumen and a deep understanding of this ever-changing industry. As a key opinion leader in the field of Interventional Oncology, Frank has a proven track record delivering highly creative, impactful solutions that will benefit Varian in our fight against cancer."
"Varian is known for keeping patients at the center of its thinking and developing the most advanced technologies to fight cancer," said Dr. Facchini. "Varian excels at bringing together the greatest scientists, clinicians and researchers to do great things to advance oncology treatment. This is the most ideal time in my career path to be joining this team."
A philosophy major at DePauw, Facchini earned his M.D. from Loyola University's Stritch School of Medicine.
Read more here.Back